Ceralasertib treatment caused increase in the percentage of tumor CD11c+MHC II+ dendritic cells (DCs) and marked up-regulation of the expression of molecules associated with DC activation: MHC class II (IAb), MHC class I (H2Kb), CD40, and CD80 (Supplementary Fig. 8D). This evidence concerns the gene ITGAX and neoplasm.